Výsledky vyhledávání - "Lisa Wetherhold"

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC)

Autor: Adam S. Kibel, Martin Gleave, Sabine D. Brookman-May, Won Kim, Christopher P. Evans, Eleni Efstathiou, Philip W. Kantoff, Ashley Ross, Neal D. Shore, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Oliver Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Weichun Xu, J. Kellogg Parsons, Kesav Yeruva, Mary-Ellen Taplin

TPS285 Background: In pts with localized high-risk PC, disease recurrence rate following RP is ̃50% (Kane et al. J Urol. 2007). Treatment (tx) with androgen blockade before RP can reduce tumor burden post RP (Taplin et al. J Clin Oncol. 2014; McKay

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7471f5ec855334535368386ed3ab903

Zobrazit plný text záznamu

PROTEUS : A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)

Autor: Mary-Ellen Taplin, Martin Gleave, Christopher P. Evans, Eleni Efstathiou, Philip W. Kantoff, Ashley Ross, Neal D. Shore, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Oliver Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Weichun Xu, Shinta Cheng, Adam S. Kibel

TPS5100 Background: Patients (pts) with localized high-risk PC experience disease progression rates of approximately 50% after RP (Kane et al. J Urol. 2007). With the approval of next-generation androgen receptor inhibitors, neoadjuvant studies have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2055af4a9337c3327b3c09e7e221ce47

Zobrazit plný text záznamu

Computational pathological identification of prostate cancer following neoadjuvant treatment

Autor: Lisa Wetherhold, Leo Grady, Shaozhou Ken Tian, Andressa Smith, Ran Godrich, Patricia Raciti, Jeremy D. Kunz, Rodrigo Ceballos, Carla Leibowitz, Angela Lopez-Gitlitz, Sabine Brookman-May, John Alvarez, Thomas J. Fuchs, Christopher Kanan, Belma Dogdas, Sharon Anne McCarthy, Adam Casson, Oliver Brendan Rooney

Publikováno v: Journal of Clinical Oncology. 38:e14052-e14052

e14052 Background: The need for accurate pathological identification and quantitation of prostate cancer (PC) following neoadjuvant treatment with androgen deprivation therapy (ADT) and androgen receptor antagonists is increasing as PC treatment cont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f763fd751f136752e3aa7eaa512eead
https://doi.org/10.1200/jco.2020.38.15_suppl.e14052

Zobrazit plný text záznamu

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)

Autor: Philip W. Kantoff, Weichun Xu, Neal D. Shore, Adam S. Kibel, Martin E. Gleave, Ashley E. Ross, Boris Hadaschik, Lisa Wetherhold, Oliver Brendan Rooney, Angela Lopez-Gitlitz, Shaozhou Ken Tian, Eleni Efstathiou, Christopher P. Evans, Axel Heidenreich, Alberto Briganti, Sabine Brookman-May, Mary-Ellen Taplin, Shinta Cheng

Publikováno v: Journal of Clinical Oncology. 38:TPS383-TPS383

TPS383 Background: Patients (pts) with localized high-risk PC have disease progression rates of ~50% after RP (Kane et al. J Urol. 2007). Neoadjuvant studies show that androgen blockade can improve local disease control at the time of RP (McKay et al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4be71a39d6cb13cffea5b065436a9cc4
https://doi.org/10.1200/jco.2020.38.6_suppl.tps383

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání